|
NGFRAP1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
2.1627144519698E-13 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
1.403420E-03 |
| Stage1-vs-Stage3 |
4.703600E-01 |
| Stage1-vs-Stage4 |
7.97350000025787E-07 |
| Stage2-vs-Stage3 |
2.201600E-03 |
| Stage2-vs-Stage4 |
5.76349999947823E-08 |
| Stage3-vs-Stage4 |
7.175800E-04 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
3.1341995665457E-10 |
| Normal-vs-Asian |
<1E-12 |
| Caucasian-vs-AfricanAmerican |
1.865170E-01 |
| Caucasian-vs-Asian |
9.515800E-01 |
| AfricanAmerican-vs-Asian |
2.140000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
7.210400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
4.30399999973297E-07 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.971500E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.263790E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.228400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.986600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.094200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.620000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.49940001817839E-09 |
| Classical-VS-Follicular |
1.44160017256922E-10 |
| Classical-VS-Other |
9.438200E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
<1E-12 |
| Tall-VS-Other |
1.469990E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
6.739600E-02 |
| Follicular-VS-Normal |
1.62481139653892E-12 |
| Other-VS-Normal |
5.95850000451037E-08 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
1.62436730732907E-12 |
| N0-vs-N1 |
1.14889999736079E-08 |
|
|
